Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OFATUMUMAB Cause Therapeutic product effect incomplete? 76 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 76 reports of Therapeutic product effect incomplete have been filed in association with OFATUMUMAB (ARZERRA). This represents 0.3% of all adverse event reports for OFATUMUMAB.

76
Reports of Therapeutic product effect incomplete with OFATUMUMAB
0.3%
of all OFATUMUMAB reports
0
Deaths
8
Hospitalizations

How Dangerous Is Therapeutic product effect incomplete From OFATUMUMAB?

Of the 76 reports, 8 (10.5%) required hospitalization, and 1 (1.3%) were considered life-threatening.

Is Therapeutic product effect incomplete Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OFATUMUMAB. However, 76 reports have been filed with the FAERS database.

What Other Side Effects Does OFATUMUMAB Cause?

Fatigue (5,202) Headache (4,430) Pain (3,382) Chills (3,372) Pyrexia (3,370) Influenza like illness (2,727) Nausea (1,688) Multiple sclerosis relapse (1,525) Covid-19 (1,435) Asthenia (1,393)

What Other Drugs Cause Therapeutic product effect incomplete?

ALBUTEROL (8,496) ADALIMUMAB (6,986) PREDNISONE (6,709) METHOTREXATE (6,037) TOFACITINIB (4,914) SECUKINUMAB (4,661) BUDESONIDE\FORMOTEROL (4,392) TIOTROPIUM (4,327) MEPOLIZUMAB (4,106) ETANERCEPT (3,961)

Which OFATUMUMAB Alternatives Have Lower Therapeutic product effect incomplete Risk?

OFATUMUMAB vs OFLOXACIN OFATUMUMAB vs OLANZAPINE OFATUMUMAB vs OLANZAPINE\SAMIDORPHAN L-MALATE OFATUMUMAB vs OLAPARIB OFATUMUMAB vs OLARATUMAB

Related Pages

OFATUMUMAB Full Profile All Therapeutic product effect incomplete Reports All Drugs Causing Therapeutic product effect incomplete OFATUMUMAB Demographics